How employers kept GLP-1 coverage without breaking the budget

A new report maps the middle ground between full coverage and benefit cuts as GLP-1 costs mount
How employers kept GLP-1 coverage without breaking the budget
GROUP BENEFITS
By Mark Rosanes
Nov 17, 2026

When a client asks whether to drop GLP-1 obesity coverage, most of the conversation centers on cost. A new report suggests the more productive question is how to structure it.

Making Obesity Care Coverage Work: Lessons From Employers examines how six US employers covering more than 30,000 workers collectively have maintained or adapted obesity benefits under real cost pressure. The report was published by the National Alliance of Healthcare Purchaser Coalitions’ Pulse of the Purchaser Research Institute (PPRI) and the Alliance for Women’s Health and Prevention (AWHP), both of which advocate for broader access to obesity care. Drawing on a survey of 49 employer and coalition representatives and 10 in-depth interviews, the study offers a set of approaches that sit between full coverage and cutting the benefit entirely.

The share of employers covering GLP-1 drugs for obesity fell from 72% in 2025 to 60% in 2026, according to the Business Group on Health, as pharmacy costs climbed to represent approximately 25% of total employer healthcare spend. The choice has largely been framed as cover it or cut it, and clients are asking their advisors to pick a side.

What the case studies show

Kalos Services, a Florida-based construction company with roughly 400 employees on a level-funded plan, introduced a capped annual household reimbursement of $2,500 for GLP-1 medications prescribed for obesity. The company modeled the financial exposure by assuming every eligible household used the full benefit, determined it fit within available plan surplus, and set a hard annual limit that makes the cost predictable. Employees fill prescriptions at a pharmacy of their choice and submit reimbursement requests through an online portal.

Patriot Rail, a short-line railroad operator, meanwhile, took a pilot-first approach. It started with 10 employees in a physician-led program that addressed the root causes of weight gain, expanded to 25 after the pilot produced measurable results, and then introduced GLP-1 coverage only for participants who met clinical eligibility criteria through the program.

“You’re either going to pay for the GLP-1 or the programs to get them in a good spot and be healthy, or you’re going to pay for the disease down the road,”  the firm's director of benefits said.

Concentra, an occupational health and urgent care provider with about 13,000 employees across 46 states, took a different approach. It kept medication coverage in place but paired it with clinical and lifestyle eligibility requirements, and added a separate virtual weight-management program for employees who do not qualify for medication.

With women representing about two-thirds of its workforce, the company also expanded women’s health services, including perimenopause and menopause support, alongside the obesity benefit, treating the two as complementary rather than separate priorities.

A large insurance brokerage firm with about 13,000 US employees, approximately 95% of them in self-insured plans, that built a virtual care pathway within its existing medical and pharmacy benefits. With roughly 80% of plan members enrolled in high-deductible plans, out-of-pocket costs had been a barrier to access even when coverage technically existed.

The firm set a flat $200 monthly medication copay that bypasses the deductible, with manufacturer coupons available to reduce that further to approximately $100 per month. The company reported 84% medication adherence among program participants, compared with rates in the 60s for other employees taking GLP-1s outside the program. Participants in the 18-month cohort had lost an average of 40 pounds. These figures are employer-reported and were not independently verified by the researchers.

The design details that determine access

Coverage on paper does not equal access in practice. Eligibility thresholds, participation requirements, cost-sharing structures, and restrictions on treatment duration all determine whether employees can actually start and stay on treatment. Advisors framing GLP-1 decisions purely around pharmacy spend risk missing the downstream costs that obesity-related conditions generate, including cardiovascular disease, diabetes, and musculoskeletal claims among them.

A 2024 study published in Nutrition & Diabetes, a Nature Portfolio journal, estimated that obesity and overweight were associated with $425.5 billion in healthcare and productivity-related costs to US employers and workers in 2023.

Defined-contribution tools like GLP-1 health reimbursement arrangements, meanwhile, have emerged as a middle-path option for employers looking to control exposure without eliminating access, a category the Kalos Services model closely resembles.

“As some employers pull back on obesity care coverage, others are finding ways to make it work,” said Millicent Gorham, CEO of AWHP. “Covering the full spectrum of comprehensive, evidence-based obesity care can help prevent costly complications and build a healthier, more resilient American workforce.”

“The employers featured in this report illustrate a range of approaches to financing and delivering obesity care,” said Jenny Goins, interim president and CEO of the National Alliance of Healthcare Purchaser Coalitions. “Their experiences can help other benefits leaders ask better questions about employee affordability, clinical support and how to evaluate results over time.”

Related Stories
Free newsletter

We'll keep you up-to-date with the latest breaking news, cutting edge opinion, and expert analysis affecting both your business and the industry as whole.

Free newsletter

Our daily newsletter is FREE and keeps you up - to - date with the world of Insurance. Please complete the form below and click on subscribe for daily newsletters from IB US.